R
REVOLUTION MEDICINES INC
NASDAQ: RVMD (Revolution Medicines, Inc.)
Last update: 1 hour ago69.88
-0.65 (-0.92%)
| Previous Close | 70.53 |
| Open | 71.65 |
| Volume | 2,034,225 |
| Avg. Volume (3M) | 2,269,065 |
| Market Cap | 13,509,187,584 |
| Price / Sales | 9.04 |
| Price / Book | 8.54 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Diluted EPS (TTM) | -4.01 |
| Total Debt/Equity (MRQ) | 6.46% |
| Current Ratio (MRQ) | 13.46 |
| Operating Cash Flow (TTM) | -591.31 M |
| Levered Free Cash Flow (TTM) | -349.13 M |
| Return on Assets (TTM) | -23.09% |
| Return on Equity (TTM) | -36.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Revolution Medicines, Inc. | Bullish | Bullish |
AIStockmoo Score
0.7
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.70 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.02% |
| % Held by Institutions | 105.87% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 99.00 (Truist Securities, 41.67%) | Buy |
| Median | 76.50 (9.47%) | |
| Low | 70.00 (Wells Fargo, 0.17%) | Buy |
| Average | 79.33 (13.52%) | |
| Total | 12 Buy | |
| Avg. Price @ Call | 55.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 18 Nov 2025 | 75.00 (7.33%) | Buy | 70.58 |
| HC Wainwright & Co. | 06 Nov 2025 | 73.00 (4.46%) | Buy | 61.38 |
| JP Morgan | 06 Nov 2025 | 82.00 (17.34%) | Buy | 61.38 |
| Needham | 06 Nov 2025 | 72.00 (3.03%) | Buy | 61.38 |
| 11 Sep 2025 | 66.00 (-5.55%) | Buy | 46.24 | |
| Wedbush | 06 Nov 2025 | 80.00 (14.48%) | Buy | 61.38 |
| 17 Oct 2025 | 77.00 (10.19%) | Buy | 54.10 | |
| RBC Capital | 03 Nov 2025 | 77.00 (10.19%) | Buy | 59.33 |
| Mizuho | 21 Oct 2025 | 90.00 (28.79%) | Buy | 53.49 |
| Raymond James | 17 Oct 2025 | 76.00 (8.76%) | Buy | 54.10 |
| 12 Sep 2025 | 72.00 (3.03%) | Buy | 46.55 | |
| Stifel | 16 Oct 2025 | 85.00 (21.64%) | Buy | 49.68 |
| Goldman Sachs | 12 Sep 2025 | 73.00 (4.46%) | Buy | 46.55 |
| Wells Fargo | 11 Sep 2025 | 70.00 (0.17%) | Buy | 46.24 |
| Truist Securities | 05 Sep 2025 | 99.00 (41.67%) | Buy | 40.50 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ANDERS JACK | - | 64.08 | -10,000 | -640,800 |
| GOLDSMITH MARK A | 65.83 | 64.22 | -50,000 | -3,146,900 |
| Aggregate Net Quantity | -60,000 | |||
| Aggregate Net Value ($) | -3,787,700 | |||
| Aggregate Avg. Buy ($) | 65.83 | |||
| Aggregate Avg. Sell ($) | 64.19 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GOLDSMITH MARK A | Officer | 12 Nov 2025 | Disposed (-) | 100,000 | 65.83 | 6,583,000 |
| GOLDSMITH MARK A | Officer | 12 Nov 2025 | Acquired (+) | 100,000 | 65.83 | 6,583,000 |
| GOLDSMITH MARK A | Officer | 12 Nov 2025 | Automatic sell (-) | 20,000 | 65.83 | 1,316,600 |
| GOLDSMITH MARK A | Officer | 12 Nov 2025 | Option execute | 20,000 | - | - |
| ANDERS JACK | Officer | 11 Nov 2025 | Automatic sell (-) | 10,000 | 64.08 | 640,800 |
| ANDERS JACK | Officer | 11 Nov 2025 | Option execute | 10,000 | - | - |
| GOLDSMITH MARK A | Officer | 07 Nov 2025 | Automatic sell (-) | 30,000 | 61.01 | 1,830,300 |
| GOLDSMITH MARK A | Officer | 07 Nov 2025 | Option execute | 30,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |